Home » Cipla Wins FDA Approval for Blood Pressure Generic
Cipla Wins FDA Approval for Blood Pressure Generic
Indian drugmaker Cipla won the FDA’s approval to begin marketing a generic equivalent to Gilead’s near-blockbuster hypertension drug Letairis, Cipla officials announced.
Last week, Teva announced its own generic equivalent of Letairis (Amrbistentan), which is aimed at patients with pulmonary arterial hypertension.
Gilead earned $943 million from Letairis sales last year and nearly $887 million in 2017.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May